Skip to main content

Table 1 Baseline and perioperative information before propensity score matching

From: Impact of prolonged cardiopulmonary bypass on gastrointestinal complications in cardiac surgery: a retrospective cohort study

Variable

Group

Total (N = 1444)

Normal CPB (N = 758)

Prolonged CPB (N = 686)

p-value

Age (year, N (%))

   

0.966

< 65

1313 (90.93)

689 (90.90)

624 (90.96)

 

≥65

131 (9.07)

69 (9.10)

62 (9.04)

 

Sex, N (%)

   

<0.001

Female

666 (46.12)

385 (50.79)

281 (40.96)

 

Male

778 (53.88)

373 (49.21)

405 (59.04)

 

BMI (kg/m2, N (%))

   

0.097

<23

649 (44.94)

325 (42.88)

324 (47.23)

 

≥23

795 (55.06)

433 (57.12)

362 (52.77)

 

Smoking, N (%)

162 (11.22)

62 (8.18)

100 (14.58)

<0.001

Diabetes, N (%)

32 (2.22)

18 (2.37)

14 (2.04)

0.667

Hypertension, N (%)

285 (19.74)

169 (22.30)

116 (16.91)

0.010

Stroke, N (%)

39 (2.7)

32 (4.22)

7 (1.02)

<0.001

Arrhythmia, N (%)

226 (15.65)

94 (12.40)

132 (19.24)

<0.001

History of cardiovascular surgery, N (%)

38 (2.63)

14 (1.85)

24 (3.50)

0.050

History of VH, N (%)

68 (4.71)

25 (3.30)

43 (6.27)

0.008

Preop use of VA, N (%)

169 (11.7)

77 (10.16)

92 (13.41)

0.055

Preop use of ABX, N (%)

133 (9.21)

54 (7.12)

79 (11.52)

0.004

NYHA, N (%)

   

<0.001

I

132 (9.14)

82 (10.82)

50 (7.29)

 

II

708 (49.03)

430 (56.73)

278 (40.52)

 

III

538 (37.26)

235 (31.00)

303 (44.17)

 

IV

66 (4.57)

11 (1.45)

55 (8.02)

 

LVEF (%, M (IQR))

57.00 (53.00, 59.00)

57.00 (55.00, 59.00)

56.50 (52.00, 58.00)

<0.001

WBC (×109/L, M (IQR))

5.68 (4.78, 6.88)

5.55 (4.73, 6.60)

5.84 (4.83, 7.19)

<0.001

UA (μmol/L, M (IQR))

354.00 (293.00, 416.00)

342.00 (280.00, 404.75)

362.00 (304.00, 428.00)

<0.001

Creatinine (μmoI/L, M (IQR))

74.00 (65.00, 86.00)

73.00 (64.00, 85.00)

75.00 (66.00, 87.00)

0.032

TC (mmol/L, M (IQR))

3.90 (3.27, 4.59)

3.94 (3.31, 4.60)

3.89 (3.23, 4.57)

0.258

LDL (mmol/L, M (IQR))

2.50 (2.03, 3.00)

2.52 (2.07, 3.01)

2.49 (2.01, 2.99)

0.250

GLU (mmol/L, M (IQR))

4.80 (4.45, 5.32)

4.79 (4.42, 5.24)

4.82 (4.47, 5.45)

0.022

Status of the operation, N (%)

   

<0.001

Elective

1391 (96.33)

756 (99.74)

635 (92.57)

 

Urgent

45 (3.12)

1 (0.13)

44 (6.41)

 

Emergency

8 (0.55)

1 (0.13)

7 (1.02)

 

Aortic surgery, N (%)

104 (7.2)

25 (3.30)

79 (11.52)

<0.001

MAZE procedure, N (%)

44 (3.05)

22 (2.90)

22 (3.21)

0.737

Transfusion of blood, N (%)

624 (43.21)

236 (31.13)

388 (56.56)

<0.001

Cross-clamp time, (min, M (IQR))

82 (62, 111)

64 (54, 75)

113 (97, 132)

<0.001

MHCA, N (%)

50 (3.46)

3 (0.40)

47 (6.85)

<0.001

Type of surgery, N (%)

   

<0.001

Aortic valve

722 (50)

403 (53.17)

319 (46.50)

 

Mitral valve

188 (13.02)

106 (13.98)

82 (11.95)

 

Tricuspid valve

32 (2.22)

20 (2.64)

12 (1.75)

 

Aortic+mitral valve

145 (10.04)

23 (3.03)

122 (17.78)

 

Aortic+tricuspid valve

13 (0.9)

3 (0.40)

10 (1.46)

 

Aortic+mitral+tricuspid valve

250 (17.31)

182 (24.01)

68 (9.91)

 

Valve surgery+CABG

94 (6.51)

21 (2.77)

73 (10.64)

 
  1. CPB Cardiopulmonary bypass, BMI Body mass index, VH Virus hepatitis, VA Vasoactive agent, ABX Antibiotics, NYHA New York Heart Association, LVEF Left ventricular ejection fraction, WBC White blood cells, UA Uric acid, TC Total cholesterol, LDL Low density lipoprotein, GLU Blood glucose, MAZE Modified maze procedure, MHCA Moderate hypothermic circulatory arrest, CABG Coronary artery bypass grafting